Celera Shifts Focus To Clinical Diagnostics, Deserting Drug Development
This article was originally published in The Gray Sheet
Executive Summary
Celera Genomics will shed its small-molecule drug development programs to focus on the development of diagnostic tests and discovering proteins useful to pharmaceutical manufacturers